Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1295295.RA8NB06CGaxlr58ZhNqRXHcXKgIj1pgr7ebBNaM_kN44E130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1295295.RA8NB06CGaxlr58ZhNqRXHcXKgIj1pgr7ebBNaM_kN44E130_assertion type Assertion NP1295295.RA8NB06CGaxlr58ZhNqRXHcXKgIj1pgr7ebBNaM_kN44E130_head.
- NP1295295.RA8NB06CGaxlr58ZhNqRXHcXKgIj1pgr7ebBNaM_kN44E130_assertion description "[The progression of EOC is characterized by a series of combined epigenetic aberrations, including the most important of those determined by the loss of methylation of certain regions of DNA encoding genes such as Ras-association domain-containing family 1 [(RASSF1A) tumor suppressor], death-associated protein kinase [(DAPK) protein kinase associated with the regulation of apoptosis], human sulfa- tase-I [(hSulf-1) sulfatase, which plays a key role in the regulation of apoptosis], breast cancer 1 gene [(BRCA1) tumor suppressor gene, involved in the processes of DNA repair], and HOXAI0 (gene required to promote many transcription factors).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1295295.RA8NB06CGaxlr58ZhNqRXHcXKgIj1pgr7ebBNaM_kN44E130_provenance.
- NP1295295.RA8NB06CGaxlr58ZhNqRXHcXKgIj1pgr7ebBNaM_kN44E130_assertion evidence source_evidence_literature NP1295295.RA8NB06CGaxlr58ZhNqRXHcXKgIj1pgr7ebBNaM_kN44E130_provenance.
- NP1295295.RA8NB06CGaxlr58ZhNqRXHcXKgIj1pgr7ebBNaM_kN44E130_assertion SIO_000772 26513872 NP1295295.RA8NB06CGaxlr58ZhNqRXHcXKgIj1pgr7ebBNaM_kN44E130_provenance.
- NP1295295.RA8NB06CGaxlr58ZhNqRXHcXKgIj1pgr7ebBNaM_kN44E130_assertion wasDerivedFrom befree-2016 NP1295295.RA8NB06CGaxlr58ZhNqRXHcXKgIj1pgr7ebBNaM_kN44E130_provenance.
- NP1295295.RA8NB06CGaxlr58ZhNqRXHcXKgIj1pgr7ebBNaM_kN44E130_assertion wasGeneratedBy ECO_0000203 NP1295295.RA8NB06CGaxlr58ZhNqRXHcXKgIj1pgr7ebBNaM_kN44E130_provenance.